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Fibroblast growth factor 23 (FGF23) and parathyroid
hormone blood levels rise following progressive loss of renal
function. Here we measured parameters of phosphate
metabolism in 100 patients with autosomal dominant
polycystic kidney disease (ADPKD) in stage 1 or 2 of chronic
kidney disease, 20 patients with non-diabetic chronic kidney
disease, and 26 with type 2 diabetes. Twenty healthy
volunteers served as controls. The mean levels of FGF23
were significantly (4-fold) higher in ADPKD compared to
non-diabetic and diabetic patients, and healthy volunteers.
Mean serum phosphate levels were significantly lower in
ADPKD patients compared to non-diabetic and diabetic
patients, and the healthy volunteers. The prevalence of
hypophosphatemia was 38, 25, 27, and 5% in ADPKD,
non-diabetic and diabetic patients, and healthy volunteers,
respectively. The tubular maximum of phosphate
reabsorption per glomerular filtration rate was lowest in
ADPKD patients with a significantly high positive correlation
with serum phosphate levels. Estimated glomerular filtration
rates were approximately 100ml/min per 1.73m2 in all
groups and parathyroid hormone and vitamin D metabolite
levels were in the normal range. Thus, FGF23 was
substantially elevated in ADPKD patients compared to other
CKD patients matched for glomerular filtration rate, and was
associated with increased renal phosphate excretion.
The mechanism for this anomaly will require further study.
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Autosomal dominant polycystic kidney disease (ADPKD) is a
slowly progressive disease, which is caused by mutations in
PKD1 or PKD2, the genes encoding for polycystin-1 and -2.
The growing cysts gradually replace the functional renal
parenchyma and distort the normal architecture of the
kidney. Typically, the volume of the kidney increases from
normal (150–200 cm3) in adolescence to 1000 cm3 in young
adults.1–2 At an age between 20 and 40 years, B50% of the
normal parenchyma is replaced by cysts. However, despite the
presence of innumerable cysts in both kidneys, glomerular
filtration rate (GFR) remains preserved up to the age of 40
years in most patients, because glomerular hyperfiltration of
functioning nephrons compensates for the ongoing loss of
functional renal tissue.3–4
Fibroblast growth factor 23 (FGF23) is primarily secreted
by osteocytes and regulates bone mineralization.5 In the
kidney, FGF23 binds to the canonical FGF receptor in the
presence of the cofactor Klotho and suppresses renal tubular
phosphate reabsorption and 1a-hydroxylase activity.6 Hyper-
phosphaturia, decreased bone mass, and osteomalacia are
hallmarks of disorders with excessive FGF23 production and
normal renal function, which include autosomal dominant
and recessive hypophosphatemic rickets,7 X-linked hypopho-
sphatemia,8 and oncogenic osteomalacia.9 Markedly elevated
circulating FGF23 levels are also found in patients with
advanced chronic kidney disease (CKD). In such patients,
the elevation of serum FGF23 levels is thought to counteract
the retention of phosphate and is classically accompanied
by a rise in parathyroid hormone (PTH) and a fall in
1,25-dihydroxyvitamin D levels.10 However, whether the rise
in serum FGF23 in patients with CKD precedes or follows the
reduction in GFR remains a matter of debate.
The objective of the present investigation was to measure
FGF23 serum levels in a cohort of ADPKD patients
with CKD stage 1 and 2 and to correlate serum FGF23 levels
with parameters of phosphate metabolism, including renal
phosphate excretion, serum PTH levels, and levels of vitamin
D metabolites. Surprisingly, FGF23 was substantially elevated
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in ADPKD patients compared with GFR-matched CKD
patients, and was associated with an apparent renal phos-
phate leak, while PTH and vitamin D metabolite levels
remained in the normal range. This suggests that the marked
increase of FGF23 in early stage ADPKD represents a
previously unrecognized manifestation of ADPKD.
RESULTS
Patient characteristics
Table 1 shows the characteristics of 100 patients with ADPKD
(mean age 31 years, 64% male), 20 patients with non-diabetic
CKD (NDCKD) (mean age 37 years, 40% male), 26 patients
with type 2 diabetes mellitus (DM2) (mean age 57 years,
81% male), and 20 healthy volunteers (mean age 32 years,
60% male). The estimated GFR was similar in all groups
(mean estimated GFR 94 ml/min per 1.73 m2 in ADPKD,
98 ml/min per 1.73 m2 in NDCKD, 92 ml/min per 1.73 m2
in patients with DM2, and 99 ml/min per 1.73 m2 in
healthy volunteers). The mean total kidney volume was
967±534 cm3 in ADPKD patients. ADPKD-related symp-
toms such as flank pain, past episodes of macrohematuria,
and cyst infection were reported in up to 30% of the patients.
Chronic glomerulonephritis was present in 18 patients of
the NDCKD patients (biopsy proven in 14 patients) and
2 patients had ischemic nephropathy. In patients with DM2,
the mean diabetes duration was 8±5 years, the mean
glycosylated hemoglobin (HbA1c) level was 8.6±1.0% and
the antidiabetic treatment included insulin and oral drugs.
The kidneys of the healthy volunteers were normal by
ultrasound examination with a mean total kidney volume of
360±80 cm3. The median urinary excretion of albumin and
the prevalence of microalbuminuria were similar in ADPKD
and NDCKD patients. None of the patients or volunteers
received treatment with vitamin D, vitamin D analogs, calcium
supplementation, phosphate binders, or bisphosphonates.
FGF23, serum phosphate, and urinary phosphate
reabsorption
The mean c-term FGF23 level in the ADPKD group
amounted to 163 relative unit (RU)/ml and was significantly
higher than in NDCKD patients (44 RU/ml), patients
with DM2 (40 RU/ml), and healthy volunteers (28 RU/ml)
(Table 2). The FGF23 levels were similar in NDCKD, DM2,
and healthy volunteers groups. ADPKD patients (99%), none
of NDCKD patients, 15% of patients with DM2, and none of
the healthy volunteers had a c-term FGF23 level 4100 RU/ml.
The difference between ADPKD patients and the other two
patient groups with CKD remained significant independent
of the level of albuminuria, estimated GFR, measured
creatinine clearance, or the presence of hypertension. The
higher c-term FGF23 levels in ADPKD patients were
independent of renal function and age (Figure 1).
Intact FGF23 and c-term FGF23 levels were measured simul-
taneously in a subset of 10 serum samples of ADPKD patients.
There was a highly significant correlation between c-term FGF23
levels measured by the Immutopics assay and intact FGF23 levels
measured by the Kainos assay (r2¼ 0.68, P¼ 0.003) without
difference between the assay means (0±39 RU/ml, P¼ 0.99).
Table 1 | Characteristics of patients with ADPKD, DM2, or NDCKD, and of HVsa
Characteristic ADPKD, N=100 NDCKD, N=20 DM2, N=26 HV, N=20
Age (years) 31 (6) 37 (17) 57 (10) 32 (5)
Sex, n (%)
Female 36 (36) 12 (60) 5 (19) 8 (40)
Male 64 (64) 8 (40) 21 (81) 12 (60)
BMI (kg/m2) 24 (4) 24 (3) 30 (3) 24 (2)
Estimated GFR (ml/min per 1.73m2)b 94 (18) 98 (18) 92 (14) 99 (12)
Chronic kidney disease classification, n (%)c
Stage 1 53 (53) 13 (65) 14 (54) —
Stage 2 46 (46) 7 (35) 12 (46) —
Stage 3 1 (1) 0 (0) 0 (0) —
Urinary albumin excretion (mg/day) 47 (27–97) 44 (14–264) 10 (5–17) 6 (4–9)
Blood pressure (mmHg)
Systolic 131 (16) 131 (8) 131 (11) 123 (7)
Diastolic 83 (11) 84 (5) 85 (10) 74 (6)
Antihypertensive treatment, n (%)
ACEi/ARB 37 (37) 16 (80) 18 (69) 0 (0)
Thiazide diuretic 9 (9) 1 (5) 10 (38) 0 (0)
Others 7 (7) 0 (0) 5 (19) 0 (0)
Abbreviations: ACEi/ARB, angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker; ADPKD, autosomal dominant polycystic kidney disease ; BMI, body mass
index; DM2, type 2 diabetes mellitus; GFR, glomerular filtration rate; HV, healthy volunteer; NDCKD, non-diabetic chronic kidney disease.
aTable shows the mean (s.d.), the median (interquartile range), or number of patients (%).
bThe GFR was estimated by using the Chronic Kidney Disease Epidemiology Collaboration equation.36
cChronic kidney disease was classified according to the Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation.37 Stage 1 denotes GFR rate
(ml/min per 1.73m2) 490; stage 2, 60–89; and stage 3, 30–59.
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As FGF23 promotes phosphate excretion by the kidney,
we examined phosphate metabolism in detail. Table 2 shows
that the mean serum phosphate levels were lowest in ADPKD
patients (0.92 mmol/l in ADPKD patients, 1.04 mmol/l in
NDCKD patients, 0.96 mmol/l in DM2 patients, and
1.01 mmol/l in healthy volunteers). The mean difference
(95% confidence interval) of serum phosphate levels between
ADPKD and NDCKD patients was 0.11 (0.21 to 0.02)
mmol/l. The serum levels were similar in NDCKD, DM2, and
healthy volunteers groups. Figure 2a depicts the relative
frequency distribution per 0.1 mmol/l interval of serum
phosphate for ADPKD patients, NDCKD patients, and
healthy volunteers. The number of patients with hypopho-
sphatemia as defined by serum phosphate levelo0.87 mmol/
l was highest in the ADPKD group (38%), compared with
NDCKD patients (25%), DM2 patients (27%), and healthy
volunteers (5%). Moreover, the tubular maximum of
phosphate reabsorption per GFR (TmP/GFR) was lowest in
ADPKD patients (0.81 mmol/l glomerular filtrate (GF) in
ADPKD patients, 0.92 mmol/l GF in NDCDK patients, and
0.88 mmol/l GF in healthy volunteers). Figure 2b displays the
relative frequency distribution per 0.1 mmol/l GF interval of
TmP/GFR for ADPKD patients, NDCKD patients, and
healthy volunteers, and reveals a strong prevalence of low
TmP/GFR values in ADPKD patients compared with
NDCKD patients and healthy volunteers. There was a very
highly correlation between serum phosphate levels and TmP/
GFR in ADPKD patients (r2¼ 0.86, Po0.0001), NDCKD
patients (r2¼ 0.96, Po0.0001), and healthy volunteers
(r2¼ 0.84, Po0.0001) (Figure 2c), suggesting that hypopho-
sphatemia in all conditions was caused by a renal leak of
phosphate. None of the study participants presented with
hyperphosphatemia. The mean 24-h urinary phosphate
excretion was similar in ADPKD, NDCKD patients, and
healthy volunteers (21 mmol in ADPKD patients, 25 mmol in
NDCKD patients, and 25 mmol in healthy volunteers), and
the significant difference of FGF23 levels between ADPKD
and NDCKD patients and healthy volunteers was indepen-
dent of the daily urinary phosphate excretion (Table 2).
These data show that the renal phosphate leak causes a high
prevalence of hypophosphatemia in ADPKD patients.
PTH, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D
levels
To elucidate whether the differences in serum phosphate and
TmP/GFR were associated with differences in serum levels of
other hormones known to influence phosphate homeostasis,
serum intact PTH, 25-hydroxyvitamin D, and 1,25-dihy-
droxyvitamin D levels were measured in ADPKD patients,
NDCKD patients, and healthy volunteers. Mean intact PTH
(49±16 ng/ml in ADPKD, 35±12 ng/ml in NDCKD, and
43±16 ng/ml in healthy volunteers), 25-hydroxyvitamin D
(20±8mg/l in ADPKD, 19±10 mg/l in NDCKD, and 25±
12 mg/l in healthy volunteers), and 1,25-dihydroxyvitamin D
levels (50±15 ng/l in ADPKD, 53±27 ng/l in NDCKD, and
51±10 ng/l in healthy volunteers) remained in the normal
range in patients with CKD stage 1 and 2 and healthy volun-
teers (Figure 3). Thus, the elevation of FGF23 in patients
with ADPKD and normal or subnormal GFR appears to be a
derangement, which is specific for ADPKD and does not
appear to be related to changes in other key hormones that
regulate phosphate.
DISCUSSION
This study shows that ADPKD patients with CKD stage 1 and 2
have fourfold elevated levels of serum FGF23, whereas PTH,
25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D levels
remained in the normal range. The rise in FGF23 was
Table 2 | Parameters of phosphate metabolism in patients with ADPKD, NDCKD, or DM2, and in HVs
Parameter ADPKD, N=100 NDCKD, N=20 DM2, N=26 HV, N=20 P-value
Fibroblast growth factor 23 (RU/ml) 163 (33) 44 (18) 40 (56) 28 (22) o0.0001
Mean difference from CKD 120w Reference 3 16 —
95% CI 99–140 — 28 to 21 43 to 10 —
Serum phosphate (mmol/l) 0.92 (0.17) 1.04 (0.22) 0.96 (0.17) 1.01 (0.12) 0.007
Mean difference from CKD 0.11w Reference 0.08 0.02 —
95% CI 0.21 to 0.02 — 0.18 to 0.04 0.15 to 0.10 —
TmP/GFR (mmol/l per glomerular filtration) 0.81 (0.18) 0.92 NA 0.89 (0.12) 0.04
Mean difference from CKD 0.10w Reference — 0.04 —
95% CI 0.21 to 0.01 — — 0.16 to 0.09 —
24-h renal phosphate excretion (mmol per 24 h) 21 (13) 25 (10) NA 25 (11) 0.2
Mean difference from CKD 4 Reference — 1 —
95% CI 11 to 3 9 to 10
Measured creatinine clearance (ml/min per 1.73m2) 99 (25) 111 (18) NA 113 (49) 0.1
Mean difference from CKD 11 Reference — 2 —
95% CI 29 to 6 — — 20 to 24 —
Abbreviations: ACEi/ARB, angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker; ADPKD, autosomal dominant polycystic kidney disease ; BMI, body mass
index; CI, confidence interval; CKD, chronic kidney disease; DM2, type 2 diabetes mellitus; GF, glomerular filtration; GFR, glomerular filtration rate; HV, healthy volunteer;
NDCKD, non-diabetic chronic kidney disease; TmP/GFR tubular maximum phosphate reabsorption per GFR.
*Table shows the mean (s.d.).
wSignificant for an a level of 0.05, post hoc Dunnett’s test with NDCKD values as reference.
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accompanied by a renal leak of phosphate, as evidenced by the
strong prevalence of low TmP/GFR and by the tight and positive
correlation between TmP/GFR and serum phosphate levels.
Stated in another way, FGF23 appears to be functionally active, at
least at the level of the renal phosphate transport.
Conceptually, FGF23 secretion in CKD is meant to be
triggered by phosphate retention as a counteracting mechanism
to restore neutral phosphate balance in the face of decreased
renal function. In our study, mean estimated GFR and measured
creatinine clearance were B100 ml/min in ADPKD patients.
Thus, it appears unlikely that retention of phosphate due to
impaired renal function triggered FGF23 secretion. Moreover, in
two separate cohorts of CKD stage 1 and 2 patients, FGF23 levels
were comprised within the normal range. Therefore, the
observation made herein appears as specific for ADPKD.
Previous studies have examined FGF23 levels in patients
at early CKD stages. Firstly, it is noteworthy that the
serum levels of FGF23 and of phosphate previously reported
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Figure 2 | Serum phosphate and tubular maximum phosphate
reabsorption frequency intervals and their correlation. Relative
frequency distribution (a) per 0.1mmol/l interval of serum phosphate
(PO4) and (b) per 0.1mmol/ml for tubular maximum phosphate
reabsorption per glomerular filtration rate (TmP/GFR) in 100 patients
with autosomal dominant polycystic kidney disease (ADPKD), 20
non-diabetic chronic kidney disease patients (NDCKD), and 20
healthy volunteers (HV). (c) Correlation between TmP/GFR and serum
PO4 in 100 ADPKD patients (r
2¼ 0.86, 95% confidence interval (CI)
0.90–1.06, Po0.0001), 20 NDCKD patients (r2¼ 0.96, 95% CI 0.85–1.08,
Po0.0001), and in 20 HVs (r2¼ 0.84, 95% CI 0.76–1.18, Po0.0001).
Symbols represent individual patients; bold circles indicate ADPKD
patients, open squares NDCKD patients, and open circles HV.
Respective lines of linear regression are shown for each group.
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Figure 1 | Fibroblast growth factor 23 versus estimated GFR
and age. (a) Scatter plot of carboxy-terminal fibroblast growth
factor 23 (c-term FGF23) levels versus estimated glomerular
filtration rate (eGFR) and (b) versus age of 100 patients with
autosomal dominant polycystic kidney disease (ADPKD), 20
patients with non-diabetic chronic kidney disease (NDCKD), 26
patients with type 2 diabetes mellitus (DM2), and 20 healthy
volunteers (HV). Symbols represent individual patients; bold
circles indicate ADPKD patients, open squares NDCKD patients,
open triangles DM2, and open circles HV.
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in patients with CKD 1 and 211–17 were similar to those
obtained in our patient groups with diabetic and non-
diabetic nephropathy. Fliser et al.12 studied FGF23 concen-
tration as a marker for CKD progression and found that the
levels of FGF23 steadily increased with decreasing levels of
GFR. In that study, CKD patients at stage 1 displayed
c-terminal FGF23 levels of 57 RU/ml that increased to 81
RU/ml in CKD stage 2, values that are significantly lower
than those measured in our ADPKD cohort. Mean serum
phosphate levels were not decreased in CKD stage 1
(1.02 mmol/l) and 2 (1.0 mmol/l) and showed a tendency
to increase in CKD stage 3 (1.08 mmol/l). In the study by
Gutierrez et al.,11 CKD stage 1 and 2 patients were reported
to have a mean c-term FGF23 levels of 86 RU/ml, like in the
study of Fliser et al., and serum phosphate values were also
reported to be within the normal range with a tendency to
rise with decreasing renal function. Notably, both studies
reported a parallel increase of intact PTH levels that was
already apparent at CKD stage 2, whereas in our study,
PTH levels were normal, further indicating an indepen-
dent mechanism of enhanced FGF23 secretion in ADPKD
patients. In both aforementioned studies by Fliser et al.
and Gutierrez et al., 3 and 16%, respectively, of the study
participants were ADPKD patients; however, GFR and FGF23
levels were not reported for this subgroup of patients.
Our findings demonstrate that ADPKD patients display
FGF23 levels that are inappropriately high for the degree
of severity of renal insufficiency, which mediate a renal
phosphate leak and consequently lead to low serum levels of
phosphate. Our study suggests that the high levels of FGF23
observed in ADPKD patients are specific to that disease.
What could be the explanation for this specificity? FGF23 is
also expressed in the liver18 and ADPKD involves the liver
that could have altered the metabolism of FGF23. However,
in our cohort of young ADPKD patients, only 5% of them
showed cystic liver disease and in most of them only few liver
cysts were detected by magnetic resonance imaging. As in all
ADPKD patients liver enzymes were in the normal range (data
not shown), we considered unlikely that the aforementioned
disorder of FGF23 metabolism could originate in the liver.
The Immutopics FGF23 assay detects c-terminal frag-
ments along with its biologically active moiety. It may be
speculated that these fragments accumulate in patients with
ADPKD due to an altered metabolism, which could account
for the elevated c-term FGF23 levels. Therefore, we measured
intact FGF23 using the Kainos assay in a subset of ADPKD
patients. The difference of the mean between these two assays
was very small, indicating that FGF23 fragments did not
accumulate in our ADPKD patients and that the elevated
levels of c-term FGF23 reflect biologically active FGF23, what
is further supported by the observed renal leak of phosphate.
Actually, our results are in line with a previous study in which
the relationship between different FGF23 assays were tested
in normophosphatemic individuals.19
It is fair to state that the stimulus driving FGF23 secretion
in patients with CKD is incompletely understood. It is
tempting to postulate that the synthesis of FGF23 is induced
by changes in intracellular phosphate in response, for instance, to
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Figure 3 | Fibroblast growth factor 23, parathyroid hormone, and vitamin D metabolites stratified for estimated GFR.
(a) Carboxy-terminal fibroblast growth factor 23 (c-term FGF23), (b) intact parathyroid hormone (iPTH), (c) 25-hydroxyvitamin D (25(OH) D),
and (d) 1,25-dihydroxyvitamin D (1,25(OH)2 D) levels stratified for estimated glomerular filtration rate (eGFR) between 60 and o90, and
490ml/min per 1.73m2 in patients with autosomal dominant polycystic kidney disease (ADPKD), non-diabetic chronic kidney disease
(NDCKD) patients, and healthy volunteers (HV).
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chronic loads in dietary phosphate. Along that line it could be
speculated that for unknown reasons our ADPKD patients
would chronically ingest more phosphate than the volunteers
and CKD patients, and that this higher amount of phosphate
would be triggering an increase of FGF23 secretion.20 However,
such was not the case because there was no difference in the 24-h
urine excretion rate of phosphate between the three groups. In
addition, Isakova et al.21 showed that an acute oral phosphate
and calcium load did not change FGF23 levels in normo-
phosphatemic and normocalcemic CKD patients, and it would
be surprising that differences in phosphate intake among the
four groups could explain a fourfold increase of FGF23 levels in
ADPKD patients.
Although renal cysts are the most prominent feature of the
disease, ADPKD is a systemic disorder that involves the heart
and vessels, liver, pancreas, and lung.22–24 Interestingly,
polycystin-1 is highly expressed in osteoblasts and osteocytes,
the main sources for FGF23 production.25 Targeted disrup-
tion of Pkd1 in mice causes severe defects in bone
development, suggesting that polycystin-1 has a major role
in the embryonic formation of cartilage and bone.26–30
Conditional disruption of Pkd1 in osteoblasts leads to bone
loss in mice, suggesting that polycystin-1 regulates bone
metabolism, although the mechanism still needs to be
determined.31 It could be hypothesized that polycystin-1 is
directly implicated in the regulation of FGF23 production,
and that a genetic defect of polycystin-1 as the one occurring
in ADPKD is responsible for the increased FGF23 secretion.
In contrast to the role of polycystin-1 in bone formation and
metabolism in rodents, an ADPKD specific alteration of bone
metabolism has so far not been reported in human ADPKD
disease. Thus, the clinical consequences of an enhanced
FGF23 secretion in ADPKD patients are currently unknown.
In conclusion, the finding of elevated FGF23 levels in
ADPKD with normal renal function, normal PTH ,and apparent
renal leak of phosphate represents a previously unrecognized
manifestation of ADPKD. However, further studies are needed
to unmask the mechanism governing this disorder.
METHODS
Study participants and procedures
ADPKD patients enrolled in this study belong to the well-characterized
prospective SUISSE ADPKD cohort.32 Patients with previously known
ADPKD or with a positive family history for the disease had been
screened for enrolment and the diagnosis of ADPKD was based on
ultrasonographic diagnostic criteria.33 Patients aged 17–40 years with an
estimated creatinine clearance X70 ml/min were enrolled. As a
comparison to the ADPKD cohort, we studied patients with DM2,
aged 418 years with an HbA1c level 47.5% and an estimated GFR
X70 ml/min, patients with NDCKD, aged 418 years with an
estimated GFR X70 ml/min, and healthy volunteers, aged 17–40 years
without history of renal disease, hypertension, or diabetes.
Detailed medical history was obtained from all patients and
healthy volunteers, including previous hospitalization and medica-
tion. Sitting blood pressure was measured by a nurse after a rest of
5 min. Subjects were declared as having arterial hypertension
if systolic blood pressure (SBP) and/or diastolic blood pressure
(DBP) were found elevated (SBP X140 mm Hg, DBP X90 mm Hg)
or treatment with an antihypertensive drug was recorded. On the
morning of the study day and after an overnight fast, a blood sample
was drawn. A 24-h urine collection was obtained on the day before
the visit to the clinic. A fasting spot urine sample was collected after
voiding the first urine of the day before attending the clinics in
ADPKD patients and volunteers. Serum and spot urine aliquots
were stored at –801C before analysis. Blood was analyzed for
FGF23, PTH, phosphate, creatinine, 25-hydroxyvitamin D, and
1,25-dihydroxyvitamin D. Spot urine was analyzed for phosphate
and creatinine. The 24-h urine was analyzed for creatinine
and phosphate in the ADPKD, NDCKD, and healthy volunteer
group. All ADPKD patients underwent renal magnetic resonance
imaging without contrast media. Total kidney volumes were
estimated from magnetic resonance imaging sequences as reported
previously.2 The healthy volunteers underwent renal ultrasonogra-
phy and the kidney volumes were estimated by applying the ellipsoid
formula.34
All patients were studied at the University Hospital of Zu¨rich,
Switzerland, between January 2004 and May 2010. The study was
conducted according to the Declaration of Helsinki and the
guidelines of Good Clinical Practice. Study approval was obtained
from the local ethics committee, and all patients and healthy
volunteers gave written, informed consent.
Analytical methods
The levels of carboxy-terminal FGF23 (c-term FGF23, first
generation, Immutopics, San Clemente, CA), intact FGF23 (intact
FGF23, Kainos Laboratories, Tokyo, Japan), and intact PTH
(Biomerica, Newport Beach, CA) were measured by enyme-linked
immunosorbent assay according to the manufacturer’s protocol.
Serum 25-hydroxyvitamin D has been determined using the RIA-kit
from Diasorin (Stillwater, MN) and serum 1,25-dihydroxy vitamin
D was measured by radioimmunoassay (Immunodiagnostic systems,
Fountain Hills, AZ). Phosphate concentrations were measured in
serum and urine using standard methods. Creatinine was measured
with the use of a modified Jaffe method traceable to an isotope-
dilution mass spectroscopy. Albumin was measured on an Integra
system (Roche, Rotkreuz, Switzerland), using immunoturbidimetry.
Inter- and intra-assay coefficient of variation were o5% for the
determination of albumin, creatinine, and phosphate, o10% for
the quantification of 25-hydroxyvitamin D, and o13% for 1,25-
dihydroxyvitamin D. TmP/GFR in mmol/l of GF was calculated
according to the formula of Brodehl.35 The GFR was estimated by
using the Chronic Kidney Disease Epidemiology Collaboration
equation.36 Hypophosphatemia and hyperphosphatemia were defined
as serum phosphate levels o0.87 and 41.45 mmol/l, respectively.
Statistical analysis
Differences among the four groups were compared by one-way
analysis of variance. When the difference was significant, statistical
comparison of the ADPKD with the NDCKD patients, DM2
patients, and healthy volunteers were performed, using Dunnett’s
post hoc test with the NDCKD as reference group. Differences among
these groups in categorical data were compared by the w2-test.
Univariate Pearson’s correlation was used to test for associations
between continuous variables. All P-values were two sided for the
comparison between the groups and values o0.05 were considered
as statistically significant. Statistical analyses were performed using
SAS statistical software version 9.2 (SAS Institute, Cary, NC).
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